Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Agios Pharmaceuticals (AGIO) Equity Average (2016 - 2025)

Historic Equity Average for Agios Pharmaceuticals (AGIO) over the last 13 years, with Q3 2025 value amounting to $1.3 billion.

  • Agios Pharmaceuticals' Equity Average rose 1603.3% to $1.3 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.3 billion, marking a year-over-year increase of 1603.3%. This contributed to the annual value of $1.2 billion for FY2024, which is 2302.2% up from last year.
  • As of Q3 2025, Agios Pharmaceuticals' Equity Average stood at $1.3 billion, which was up 1603.3% from $1.4 billion recorded in Q2 2025.
  • Agios Pharmaceuticals' Equity Average's 5-year high stood at $2.0 billion during Q2 2021, with a 5-year trough of $702.2 million in Q2 2024.
  • In the last 5 years, Agios Pharmaceuticals' Equity Average had a median value of $1.2 billion in 2022 and averaged $1.2 billion.
  • As far as peak fluctuations go, Agios Pharmaceuticals' Equity Average soared by 23946.34% in 2021, and later tumbled by 4197.95% in 2022.
  • Quarter analysis of 5 years shows Agios Pharmaceuticals' Equity Average stood at $1.3 billion in 2021, then dropped by 19.94% to $1.1 billion in 2022, then dropped by 21.07% to $848.9 million in 2023, then soared by 86.57% to $1.6 billion in 2024, then decreased by 16.22% to $1.3 billion in 2025.
  • Its Equity Average stands at $1.3 billion for Q3 2025, versus $1.4 billion for Q2 2025 and $1.5 billion for Q1 2025.